Pharmaceuticals, Biotechnology and Life Sciences
Horizon Pharma has announced that the Phase 3 trial, Steadfast (Safety, Tolerability and Efficacy of Actimmune Dose Escalation in Friedreich’s Ataxia study), evaluating Actimmune (interferon gamma-1b) for…
Horizon Discovery Group has entered into an Original Equipment Manufacturer (OEM) agreement with CareDx…
Horizon Pharma has announced its third-quarter 2016 financial results on Monday.
Horizon Pharma has announced that Ravicti (glycerol phenylbutyrate) Oral Liquid is now available in Canada through its affiliate….
Horizon Pharma has completed the acquisition of Raptor Pharmaceutical…
Horizon Pharma, with its wholly owned subsidiaries, Horizon Pharma, Inc. and Horizon Pharma USA, Inc., intends to offer $300 million aggregate principal amount of senior notes due 2024, and to borrow $375 million.
Horizon Pharma and Raptor Pharmaceutical Corp.have entered into a definitive agreement under which Horizon Pharma will acquire all of the issued…
United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance to Horizon Pharma for U.S. patent application number…
Horizon Pharma plc has entered a definitive agreement to acquire Crealta Holdings LLC for $510 million in cash.
Horizon Pharma and its affiliate, Horizon Therapeutics, has gotten the European Commission’s (EC’s) approval for Ravicti – glycerol phenylbutyrate – Oral Liquid for use as an adjunctive therapy for chronic management patients with six subtypes of Urea Cycle Disorders (UCDs).